Health Care · Pharmaceuticals
Eli Lilly: revenue, profit and dividends
In fiscal 2025, Eli Lilly had revenue of $65.2B, up 12.6% a year on average since 2015, and net income of $20.6B (31.7% of revenue). Its dividend per share has gone up 9 years in a row, to $6.23. It has 16% fewer shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +44.7% vs 2024
- Ticker
- LLY · NYSE
- Sector
- Health Care
- Sub-industry
- Pharmaceuticals
- Headquarters
- Indianapolis, Indiana
- Founded
- 1876
- In the S&P 500 since
- December 31, 1970
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- ELI LILLY & Co · CIK 0000059478
Revenue and net income
Revenue went from $18.6B in 2007 to $65.2B in 2025. Net loss in 2008, 2017.
Diluted earnings per share
Diluted EPS went from −$1.89 in 2008 to $22.95 in 2025. Ten-year growth: 26.1% a year.
Dividends per share
Raised 9 years in a row, every year from 2017 to 2025.
Shares outstanding
15.6% fewer shares in 2025 than in 2015 (1.07B → 899M): buybacks outweighed new shares.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $8.97B in 2025, 13.8% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $65.2B | $20.6B | 31.7% | $22.95 | $6.23 | 899M | $16.8B | $7.84B | $8.97B |
| 2024 | $45B | $10.6B | 23.5% | $11.71 | $5.40 | 904M | $8.82B | $5.06B | $3.76B |
| 2023 | $34.1B | $5.24B | 15.4% | $5.80 | $4.69 | 903M | $4.24B | $3.45B | $792M |
| 2022 | $28.5B | $6.24B | 21.9% | $6.90 | $4.07 | 905M | $7.59B | $1.85B | $5.73B |
| 2021 | $28.3B | $5.58B | 19.7% | $6.12 | $3.53 | 912M | $7.37B | $1.31B | $6.06B |
| 2020 | $24.5B | $6.19B | 25.2% | $6.79 | $3.07 | 913M | $6.5B | $1.39B | $5.11B |
| 2019 | $22.3B | $8.32B | 37.3% | $8.89 | $2.68 | 936M | $4.84B | $1.03B | $3.8B |
| 2018 | $21.5B | $3.23B | 15.0% | $3.13 | $2.33 | 1.03B | $5.52B | $1.21B | $4.31B |
| 2017 | $20B | −$204M | −1.0% | −$0.19 | $2.12 | 1.05B | $5.62B | $1.08B | $4.54B |
| 2016 | $21.2B | $2.74B | 12.9% | $2.58 | $2.05 | 1.06B | $4.85B | $1.04B | $3.81B |
| 2015 | $20B | $2.41B | 12.1% | $2.26 | — | 1.07B | $2.96B | $1.07B | $1.9B |
| 2014 | $19.6B | $2.39B | 12.2% | $2.23 | — | 1.07B | $4.46B | $1.16B | $3.3B |
| 2013 | $23.1B | $4.68B | 20.3% | $4.32 | — | 1.08B | $5.74B | $1.01B | $4.72B |
| 2012 | $22.6B | $4.09B | 18.1% | $3.66 | — | 1.12B | $5.3B | $905M | $4.4B |
| 2011 | $24.3B | $4.35B | 17.9% | $3.90 | $1.96 | 1.11B | $7.23B | $672M | $6.56B |
| 2010 | $23.1B | $5.07B | 22.0% | $4.58 | $1.96 | 1.11B | $6.86B | $694M | $6.16B |
| 2009 | $21.8B | $4.33B | 19.8% | $3.94 | $1.96 | 1.1B | $4.34B | $765M | $3.57B |
| 2008 | $20.4B | −$2.07B | −10.2% | −$1.89 | $1.90 | 1.09B | $7.3B | $947M | $6.35B |
| 2007 | $18.6B | $2.95B | 15.8% | — | — | — | $5.15B | $1.08B | $4.07B |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Pharmaceuticals companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.